---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002453"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:17:35.910116+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arbutus reports Q1 2024 net loss of $17.9M, cash runway extended to Q2 2026

## Summary
- Net loss $17.9M ($0.10 per share); revenue $1.5M, down from $6.7M YoY due to lower license and royalty revenue.
- Cash, equivalents & marketable securities $137.9M; expects cash runway through Q2 2026.
- End-of-treatment data for two Phase 2a imdusiran trials to be presented at EASL June 2024.
- AB-101 oral PD-L1 inhibitor Part 1 showed dose-dependent receptor occupancy; moving to multiple-ascending dose part.
- Favorable claim construction ruling in Moderna LNP lawsuit; trial set for April 21, 2025.

## SEC filing metadata
- accession: 0001171843-24-002453
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184324002453/0001171843-24-002453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184324002453/f8k_050224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002453
- JSON: https://secwatch.observer/filing/0001171843-24-002453.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002453.txt

## Key facts
- Earnings Releases
  Arbutus Biopharma Corp reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 2, 2024, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and certain other information.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184324002453/0001171843-24-002453-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.